Enhancing Drug Development for Neuroendocrine Tumors: A novel radiomic signature to predict survival in patients enrolled in Alliance A021202
- Citation:
- Meeting Instance:
- NETRF 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster/Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U24CA196171; U10CA180863 (CCTG); U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Laurent Dercle Susan M. Geyer Timothy R. Asmis Sanja Karovic Michael Knopp Ardaman Shergill Andrew B. Nixon Spencer Behr Eileen Mary O'Reilly Jonathan R. Strosberg Jeffrey A. Meyerhardt Lawrence H Schwartz Emily K. Bergsland
- Networks:
- CA136, FL065, LAPS-IL057, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-OH007, VA002
- Study
- Alliance-A021202
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: